Copertina

The relevance of curative-intent metastasectomy in colorectal cancer patients: real-world insights from a certified comprehensive cancer center in Germany

Long-term survival in metastatic colorectal cancer (mCRC) can be achieved by curative-intent metastasectomy. Patients ineligible for upfront (primary) metastasectomy (PM) may become candidates for secondary metastasectomy (SM) following response to primary chemotherapy (PCT), still with curative int...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Holch, Julian (Autore) , Eisenburger, Jo-Ann (Autore) , Weber, Antony (Autore) , Kammermeier-Wehlau, Iris (Autore) , Wiberg, Yannick (Autore) , Allmendinger, Fabian (Autore) , Heinrich, Kathrin (Autore) , Weiss, Lena (Autore) , Westphalen, Christoph Benedikt (Autore) , Krenmayr, Victoria (Autore) , Dorman, Klara (Autore) , Zhang, Danmei (Autore) , Fey, Theres (Autore) , Berger-Thürmel, Karin (Autore) , Wirth, Ulrich (Autore) , Kühn, Florian (Autore) , von Bergwelt-Baildon, Michael (Autore) , Werner, Jens (Autore) , Heinemann, Volker (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 2026
In: International journal of cancer
Year: 2026, Pages: 1-11
ISSN:1097-0215
DOI:10.1002/ijc.70540
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.70540
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.70540
Testo
Note sull'autore:Julian W. Holch, Jo-Ann Eisenburger, Antony Weber, Iris Kammermeier-Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger-Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt-Baildon, Jens Werner, Volker Heinemann
Descrizione
Riassunto:Long-term survival in metastatic colorectal cancer (mCRC) can be achieved by curative-intent metastasectomy. Patients ineligible for upfront (primary) metastasectomy (PM) may become candidates for secondary metastasectomy (SM) following response to primary chemotherapy (PCT), still with curative intent. Most studies focus either on resectable or unresectable mCRC, limiting insights into differential subgroup benefits. Here, real-world data offer a comprehensive evaluation of PM, SM, and PCT. We analyzed real-world data from mCRC patients treated at the certified Comprehensive Cancer Center of the LMU Hospital (CCC MunichLMU) from 2007 to 2021, following ESMO's guidance for real-world evidence (GROW). Overall survival (OS) data were matched with the Bavarian Cancer Registry. OS was assessed using Kaplan-Meier estimates and Cox regression analysis, adjusting for prognostic factors, including primary tumor sidedness and number of metastatic sites. Of 840 evaluable patients, 166 (20%) underwent PM, 520 (62%) received PCT, and 109 (13%) became eligible for SM after response to systemic treatment. OS was significantly longer for PM versus PCT (82.3 vs. 41.6 months, HR = 0.47, p < 0.0001). Multivariate analysis confirmed PM benefit across all subgroups, including high-risk patients (e.g., right-sided and multisite mCRC). OS was comparable between PM and SM (82.3 vs. 80.9 months), whereas patients ineligible for local treatments had the worst OS (25 months). Both PM and SM were associated with excellent OS, also for patients with high-risk mCRC. Our findings underscore the importance of initial evaluation and continuous reassessment of resectability throughout the course of treatment against mCRC, as implemented at the CCC MunichLMU.
Descrizione del documento:Gesehen am 13.08.2026
Descrizione fisica:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.70540

Documenti analoghi